1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €6.61 (+4.92%). The median is €6.44 (+2.22%).
| Buy |
0 |
| Hold |
8 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 1.49M | 144.76% |
| Gross profit | 1.3M | 212.56% |
| Net profit | -28.5M | 21.13% |
| EBITDA | -38.49M | 66.84% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €2.33B |
Number of shares | 369.95M |
52-week high/low | €6.40 - €2.81 |
| Dividends | No |
Beta | 1.55 |
P/E ratio | -2.53 |
PEG ratio | 0.01 |
P/B ratio | 14.98 |
P/S ratio | 605.84 |
Company profile
| Name | Atai Beckley NV |
| CEO | Srinivas G. Rao |
| Headquarters | New York,
ny USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| Employees | 99 |
Discover assets
Shareholders of Atai Beckley NV also invest in the following assets
